We are live on ! Find out more
IVA icon

Inventiva
IVA

4.13 USD
+0.30
7.83%
At close Updated Nov 3, 1:37 PM EST
1 day
7.83%
5 days
11.92%
1 month
18.68%
3 months
-2.82%
6 months
-21.63%
Year to date
-13.24%
1 year
0.73%
5 years
-72.13%
10 years
-69.23%
 

About: Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.

Employees: 77

Healthcare Biotechnology

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 30%
Neutral 60%
Negative 10%
Positive
Seeking Alpha
20 days ago
Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
Inventiva receives a speculative strong buy rating, with a probability-weighted fair value of ~$15 per share versus ~$3.20 currently. Following strong Phase 2b NATIVE results, lanifibranor's pivotal Phase 3 NATiV3 readout is imminent, creating a major potential catalyst for the stock. The model yields a 40% probability of a $29 fair value per share, versus a 32% probability of near-total loss, with intermediate valuations reflecting varying degrees of clinical differentiation.
Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
Positive
MarketBeat
24 days ago
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Neutral
GlobeNewsWire
27 days ago
Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
Daix (France), New York City (New York, United States), October 6, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral small molecule therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of three abstracts at the upcoming AASLD The Liver Meeting® 2026, to be held from November 5-9, 2026, in Denver, Colorado.
Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
Neutral
MarketBeat
1 month ago
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Negative
Benzinga
1 month ago
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Neutral
Seeking Alpha
1 month ago
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Neutral
MarketBeat
1 month ago
Inventiva Q2 Earnings Call Highlights
Inventiva NASDAQ: IVA said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth quarter of 2026, after the last patient completed the study's 72-week visit earlier this month.
Inventiva Q2 Earnings Call Highlights
Neutral
Seeking Alpha
1 month ago
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
GlobeNewsWire
2 months ago
Inventiva Appoints Chris Benecchi as Chief Operating Officer
Daix (France), New York City (New York, United States), August 31, 2026 –  Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Chris Benecchi as Chief Operating Officer. A proven biopharmaceutical leader with extensive experience in building organizations, preparing medicines for launch and integrating cross-functional operations, Mr. Benecchi will lead Inventiva's operational readiness as the Company approaches its pivotal NATiV3 Phase 3 topline study results of lanifibranor, in MASH, expected in Q4 2026, and prepares for potential commercialization.
Inventiva Appoints Chris Benecchi as Chief Operating Officer
Positive
Seeking Alpha
3 months ago
Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives
Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual metabolic and anti-fibrotic benefits independent of weight loss, complementing GLP-1 and SGLT2 agents. Inventiva has secured sufficient liquidity through Q2 2027, with contingent access to further capital, and has strengthened governance ahead of the pivotal NATiV3 Phase 3 readout.
Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives
See News Rankings
Price charts implemented using Lightweight Charts™